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ABSTRACT
A high-throughput screening campaign was conducted to in-
terrogate a 380,0001 small-molecule library for novel D2 dopamine
receptor modulators using a calcium mobilization assay. Active
agonist compounds from the primary screen were examined for
orthogonal D2 dopamine receptor signaling activities including
cAMPmodulation and b-arrestin recruitment. Although themajority
of the subsequently confirmed hits activated all signaling pathways
tested, several compounds showed a diminished ability to stimulate
b-arrestin recruitment. One such compound (MLS1547; 5-chloro-7-
[(4-pyridin-2-ylpiperazin-1-yl)methyl]quinolin-8-ol) is a highly effica-
cious agonist at D2 receptor–mediated G protein–linked signaling,
but does not recruit b-arrestin as demonstrated using two different
assays. This compound does, however, antagonize dopamine-
stimulated b-arrestin recruitment to the D2 receptor. In an effort to
investigate the chemical scaffold of MLS1547 further, we charac-
terized a set of 24 analogs of MLS1547 with respect to their ability
to inhibit cAMP accumulation or stimulate b-arrestin recruitment. A
number of the analogs were similar to MLS1547 in that they
displayed agonist activity for inhibiting cAMP accumulation, but did
not stimulate b-arrestin recruitment (i.e., they were highly biased). In
contrast, other analogs displayed various degrees of G protein
signaling bias. These results provided the basis to use pharmaco-
phore modeling and molecular docking analyses to build a pre-
liminary structure-activity relationship of the functionally selective
properties of this series of compounds. In summary, we have
identified and characterized a novel G protein–biased agonist of
the D2 dopamine receptor and identified structural features that
may contribute to its biased signaling properties.
Introduction
Dopamine receptors mediate the many actions of dopamine
in the brain and periphery. In mammals, five distinct dopa-
mine receptors have been characterized, which are divided
into two subfamilies based on their structure, pharmacology,
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and signaling properties (Sibley et al., 1992). D1-like recep-
tors (D1R and D5R) are Gas/olf coupled, whereas D2-like
receptors (D2R, D3R. and D4R) are Gai/o coupled (Sibley et al.,
1992). Dopamine receptors have also been shown to signal
through recruitment and activation of the scaffolding protein
b-arrestin (Beaulieu et al., 2007a). Among the dopamine re-
ceptors, the D2R is one of the most validated drug targets
in neurology and psychiatry. However, most drugs targeting
the D2R are problematic, either being less efficacious than
desired or possessing adverse side effects due to the activation
or blockade of multiple parallel signaling pathways. Despite
recent advances, it remains unclear which signaling arms
of the D2R are involved in the therapeutic effects of various
agents used to treat neuropsychiatric disease states associ-
ated with the D2R.
One of the best characterized signaling pathways of the
D2R is Gi/Go-mediated inhibition of adenylate cyclase, which
reduces intracellular cAMP levels and thereby attenuates
phosphorylation of the 32-kDa dopamine and cAMP-regulated
phosphoprotein (DARPP-32) (Bateup et al., 2008) by protein
kinase A. DARPP-32 is a protein phosphatase that acts as an
integrator of cell signaling of many neurotransmitters,
including dopamine (Svenningsson et al., 2004). Reduction
of DARPP-32 phosphorylation inhibits its activity and
associated downstream signaling pathways (Svenningsson
et al., 2004; Bateup et al., 2008). Notably, administration of
antipsychotic drugs, such as haloperidol or clozapine, has
been shown to increase the level of DARPP-32 phosphoryla-
tion (Pozzi et al., 2003). A more recently characterized
signaling pathway for the D2R is activation of glycogen
synthase kinase 3 b (GSK3b), which is G protein–independent
and occurs through agonist recruitment of b-arrestin-2 to
the receptor. This leads to the formation of a b-arrestin–
dependent complex of protein kinase B (Akt) and protein
phosphatase 2A, which results in dephosphorylation of Akt
and subsequent activation of GSK3b (Beaulieu et al., 2007b,
2008). Interestingly, Caron and colleagues have argued that
inhibition of this pathway in D2R-expressing neurons is
correlated with antipsychotic properties (Masri et al., 2008;
Urs et al., 2012), whereas Roth and colleagues have suggested
that stimulation of the D2R–b-arrestin pathway may actually
enhance antipsychotic efficacy (Allen et al., 2011).
A promising approach to dissecting the importance of these
signaling pathways, and resolving these associated contro-
versies, is to study them using ligands that exhibit function-
ally selective or biased signaling properties (Urban et al.,
2007; Whalen et al., 2011). Many G protein–coupled receptors
(GPCRs) are able to transduce signals through more than one
intracellular pathway. Although in most cases the endoge-
nous transmitter will activate all signaling pathways,
synthetic agonists may preferentially activate one signaling
pathway over another, or even activate one while inhibiting
another (Kenakin, 2007a,b, 2008; Mailman, 2007; Urban
et al., 2007). Although the mechanisms underlying functional
selectivity are not known, a leading hypothesis is that GPCRs
can adopt multiple functionally “active” conformational states
that are either stabilized or induced by these selective ligands
(Kobilka and Deupi, 2007; Wess et al., 2008). Although
relatively few biased ligands have been described for the
D2R (Kilts et al., 2002; Mottola et al., 2002; Gay et al., 2004;
Lane et al., 2007, 2008), existing examples strongly support
the concept of the D2R being able to adopt multiple signaling-
biased confirmations. Recently, a structural basis for func-
tional selectivity of several GPCRs has been proposed (Liu
et al., 2012; Dror et al., 2013; Kruse et al., 2013; Wacker et al.,
2013; Abdul-Ridha et al., 2014) suggesting that rational
design of functionally selective compounds may be possible.
Recently, Jin and colleagues developed and characterized
a series of analogs of the atypical antipsychotic aripiprazole that
are partial agonists of D2R-mediated b-arrestin recruitment,
yet fail to stimulate Gi-linked cAMP inhibition (Allen et al.,
2011; Chen et al., 2012). In contrast, no biased ligands have been
described with the opposing pharmacology for the D2R, that is,
stimulation of G protein signaling pathways without activation
of b-arrestin recruitment. We now report the discovery of a
novel, highly efficacious G protein–biased agonist for the D2R
that also antagonizes b-arrestin recruitment to the receptor.
Identification of such functionally selective ligands may provide
the requisite pharmacological probes with which to dissect
these two signaling pathways and elucidate their function
in vivo. Functionally selective agonists may also result in im-
proved therapies for certain neuropsychiatric disorders, such as
Parkinson’s disease, in which D2R stimulation is desired, and
schizophrenia, where inhibition of D2R signaling is the goal.
Materials and Methods
CalciumMobilization Assay. Flp-In T-Rex 293 cells were stably
transfected with humanD2SR andGqi5 protein using the Flp-In T-Rex
expression system (Life Technologies, Grand Island, NY). The cell line
was constructed by cotransfecting SFD2s/FRT/TOand pOG44, followed
by hygromycin B selection. Gqi5/pIRESpuro3 (Clontech, Mountain
View, CA) was then transfected into the D2R stable cell line, followed
by selection with puromycin. D2R expression is controlled by tetra-
cycline induction, whereas Gqi5 is continuously expressed.
D2R-stimulated calcium mobilization was measured using meth-
ods similar to those previously published by our laboratory (Chun
et al., 2013). Cells were induced with 1 mM tetracycline added directly
to the culture media and plated in 384- or 1536-well, optical, clear-
bottom, black-walled plates (Greiner Bio-One, Monroe, NC). Twenty
microliters per well (20,000 cells/well) were added to 384-well plates,
and 3 ml/well (4000 cells/well) to a 1536-well plate. The next day, cells
were incubated for 60 minutes at room temperature in the dark with
Fluo-8 NW calcium dye in the presence of an extracellular signal
quencher (Screen Quest Fluo-8 NW Calcium Assay Kit; AAT
Bioquest, Inc., Sunnyvale, CA), as recommended by the manufac-
turer. The plates were then treated with various concentrations of
agonist in the presence of 0.2 mM sodium metabisulfite. Plates were
read kinetically in real time (every 0.6 second) for 2 minutes after
agonist addition. Compound additions were done in unison using
a 384-tip onboard robotic pipette (384-well assays) or an onboard
1536-pintool (1536-well assays) while continuously reading at an
excitation wavelength of 480 nm and an emission wavelength of 540
nm on a functional drug screening system (FDSS) mCell (384-well
assays) or an FDSS 7000 (1536-well assays) (Hamamatsu, Bridge-
water, NJ). Data were recorded and quantified as maximum minus
minimum (max2min) relative florescence units within the assay
window using FDSS software.
cAMP Inhibition Assay. D2R-mediated inhibition of forskolin-
stimulated cAMP production was assayed using the DiscoveRx
HitHunter assay kit (DiscoveRx Inc., Fremont, CA). CHO-K1 cells
stably expressing the human D2R long isoform (DiscoveRx) were
seeded in Cell Plating Media 2 (DiscoveRx Inc.) at a density of 5000
cells/well in 384-well black, clear-bottom plates. After 16–24 hours of
incubation at 37°C, 5% CO2, and 90% humidity, the medium was
removed and replaced with 5 ml/well phosphate-buffered saline (PBS).
Cells were treated with 2.5 ml of various concentrations of compound
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diluted in PBS in the presence of an ∼EC80 concentration of forskolin
(100 mM) and 0.2 mM sodium metabisulfite and incubated for 60
minutes at 37°C, 5% CO2, and 90% humidity. DiscoveRx HitHunter
reagents were then added, and cells were incubated in the dark at room
temperature, according to manufacturer recommendations. Lumines-
cencewasmeasured on aHamamatsuFDSSmCell (Hamamatsu) for 8.5
seconds. Data were collected as relative luminescence units (RLUs), and
values were normalized to a percentage of the maximum forskolin-
stimulated cAMP signal. Data fit to a single site model and the Hill
coefficients of the concentration response curves did not significantly
differ from unity.
b-Arrestin Recruitment Assay. The ability of the agonist-
activated receptor to recruit b-arrestin-2 was determined using the
DiscoveRx PathHunter technology (DiscoveRx) that involves enzyme
complementation of fusion-tagged receptor along with an arrestin
recruitment modulating sequence and b-arrestin-2 proteins. Control
experiments determined that this PathHunter receptor construct will
couple to G protein–mediated signaling with similar efficacy as an
unmodified construct (data not shown). Assays were conducted, with
minor modifications, as previously published by our laboratory
(Banala et al., 2011; Bergman et al., 2013). In brief, CHO-K1 cells
expressing D2R long isoform (DiscoveRx) were seeded in Cell Plating
Media 2 (DiscoveRx) at a density of 2625 cells/well in 384-well black,
clear-bottom plates. Following 24 hours of incubation, the cells were
treated with multiple concentrations of compound in PBS containing
1% dimethylsulfoxide and incubated at 37°C for 90 minutes. DiscoveRx
reagent was then added to cells according to the manufacturer’s rec-
ommendations followed by a 30–60-minute incubation at room tem-
perature. Luminescence was measured on a Hamamatsu FDSS mCell
reader. Data were collected as RLUs and subsequently normalized to a
percentage of the control luminescence seen with a maximum concen-
tration of dopamine, with 0% being RLUs seen in the absence of any
compound. The Hill coefficients of the concentration response curves did
not significantly differ from unity.
b-Arrestin Bioluminescence Resonance Energy Transfer
Assay. To directly assess induction of D2R–b-arrestin-2 interaction,
we used a bioluminescence resonance energy transfer (BRET) assay
that utilizes a cell line stably transfected with an Rluc-8 fusion-tagged
D2R (short isoform) under a tetracycline-inducible promoter, as well as
mVenus fusion-tagged b-arrestin-2 (Hamdan et al., 2005; Klewe et al.,
2008). The cell line was constructed using Flp-In T-Rex 293 cells
(Invitrogen, Life Technologies) transfected with pIRESpuro3/mVenus/
b-arrestin-2, where the mVenus tag is on the N terminus of the human
b-arrestin-2. Clones were then analyzed for expression of the construct
following selection with 2 mg/ml puromycin. The cell line with the
highest level of expressionwas then transfectedwith pcDNA5/FRT/TO-
SFD2LRluc-8 and POG44 followed by hygromycin selection and
subsequent functional screening to select the final stable line. Addition
of the Rluc-8 substrate coelenterazine h results in an emission at 485
nm. However, when in close proximity to mVenus, resonance energy
transfer leads to a shift in the emission spectrum from 485 to 510–540
nm, thereby quantifying the interaction between the receptor and the
b-arrestin-2 protein. Cells were induced for 24 hours by addition of
1 mM tetracycline directly to the culture media, resulting in membrane
receptor expression of approximately 5.8 pmol/mg protein. Cells were
then removed from the plates using Earle’s balanced salt solution
without calcium (EBSS2), pelleted by centrifugation, resuspended
(200,000 cells/ml) in Dulbecco’s phosphate-buffered saline (Mediatech,
Manassas, VA) plus 0.05 g/500 ml sucrose, and seeded into 96-well,
solid-bottom white assay plates (20,000 cells/well) (Greiner Bio-One).
Cells were allowed to sit for 45 minutes at room temperature and were
then treated with 5 mM coelenterazine h (Nanolight Technology,
Pinetop, AZ), incubated for 5 minutes, and then stimulated with
agonist using an onboard robotics 8-channel pipet head in a Flexstation
III (Molecular Devices, Sunnyvale, CA). Original data were collected
5 minutes after agonist addition as a ratio of 525/485-nm emission.
Data are expressed as normalized to the percentage of the maximum
dopamine-induced ratio.
Radioligand Binding Assays. Radioligand competition binding
assays were conducted with slight modifications as previously de-
scribed by our laboratory (Chun et al., 2013). Human embryonic kidney
293 cells stably transfected with human D1R, D2R, D3R, D4R, or D5R
(Codex Biosolutions, Inc., Gaithersburg, MD) were dissociated from
plates using EBSS2, and intact cells were collected by centrifugation at
900g for 10 minutes. Cells were resuspended and lysed using 5 mM
Tris-HCl and 5 mMMgCl2 at pH 7.4 at 4°C. Cell lysate was pelleted by
centrifugation at 30,000g for 30minutes and resuspended inEBSSwith
calcium at pH 7.4. Cell lysates (100 ml, containing ∼8 mg of protein for
D2-like receptor assays or ∼10mg of protein for D1-like receptor assays)
were incubated for 90 minutes at room temperature with the indicated
concentrations of MLS1547 (5-chloro-7-[(4-pyridin-2-ylpiperazin-1-yl)
methyl]quinolin-8-ol) and either 0.5 nM [3H]SCH23390 (8-chloro-3-
methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol) (D1R and D5R)
or 0.5 nM [3H]methylspiperone (D2R, D3R, and D4R) in a final reaction
volume of 250 ml. Nonspecific binding was determined in the presence
of 4 mM (1)-butaclamol. Bound ligand was separated from free by
filtration through a PerkinElmer Unifilter-96 GF/C 96-well microplate
using the PerkinElmer Unifilter-96 Harvester (PerkinElmer, Waltham,
MA), washing three times with 1 ml/well ice-cold assay buffer. After
drying, 50ml of liquid scintillation cocktail (MicroScint PS; PerkinElmer)
was added to each well, and plates were sealed and analyzed on a
PerkinElmer Topcount NXT.
Pharmacophore Modeling. All modeling was performed using
tools in the Schrödinger suite (Schrödinger Inc., New York, NY).
Although the main goal of pharmacophore modeling is to explain the
molecular features that are associated with active compounds, such
capability can benefit from the inclusion of “inactive” compounds in the
model-building procedure. In our case, to differentiate G protein–
biased from G protein–nonbiased agonists in such a model, we defined
a so-called “biased activity” measure that is similar to the “bias” factor













For G protein–biased agonists that did not exhibit measurable
b-arrestin stimulation, we used the log10 (Emax/EC50) values from
the cAMP assay to quantitate the biased activity of these ligands.
Based on the biased activity calculations described earlier, 10
compounds displaying either the strongest or weakest G protein bias
were selected: NCGC9125, NCGC9126, NCGC6387, NCGC9141, and
MLS1547 for the biased set, andNCGC9134, NCGC9132, NCGC5872,
NCGC9131, and NCGC6388 for the nonbiased set (see Results and
Discussion). For each compound, the three-dimensional structure was
built using the program Maestro (version 9.5; Schrödinger LLC), and
a single protonation state was chosen, with the 4 position of the
piperazine bearing the positive charge in all cases. Multiple con-
formers were generated using the ConfGen program (version 2.5;
Schrödinger LLC). At least 10 conformers per ligand were generated,
which required sampling with the “intermediate” search strategy of
the program.
The goal of a pharmacophore search is to identify the largest set of
pharmacophore features with specific three-dimentional relation-
ships, i.e., interfeature distances that are common among all active
compounds. The pharmacophore model was built using the program
Phase (version 3.6; Schrödinger LLC). The default pharmacophore
features include positive (P), negative (N), hydrogen-bond acceptor
(A), hydrogen-bond donor (D), aromatic (R), and hydrophobic (H)
types. For the compounds studied here, the following functional
groups were assigned to the H feature using a procedure that has been
described in Greene (1994): isopropyl, aromatic halogens, aromatic
CH3, and methoxy-CH3. The location of a given hydrophobic site is
a weighted average of the positions of the nonhydrogen atoms in the
associated fragment.
In addition, to allow ambiguous alignment of nonpolar features,
aromatic groups in the ligands were assigned to both the R and H
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feature types. When we assigned these features to the selected
ligands, the largest number of features in a pharmacophore hypoth-
esis that producedmatches for all five biased compounds was found to
be 4. These 4-point pharmacophores were of the HHPR, AHHP,
HPRR, and AHPR variants (the order of the features is arbitrary). For
each of these variants, a number of three-dimensional hypotheses
were enumerated and clustered based on all occurring interfeature
distances. From this initial set of hypotheses, the one that best
matched the actives was then determined by a more rigorous custom
scoring function (“survival score”), which consisted of 1) the alignment
score based on the root-mean-square-deviation of feature positions, 2)
the vector score of aligned features with a directional character
(aromatic, donor, and acceptor), and 3) the pairwise volume overlap of
all the ligands aligned to the pharmacophore. This default scoring of
all possible variants revealed that the HHPR and HRPR hypotheses
were best able to explain the data. To eliminate the hypotheses that
also matched the nonbiased compounds, the five most nonbiased
compounds were used to rescore the hypotheses (“inactive score”). The
finally selected pharmacophore was the HRPR variant (see Results
and Discussion) with the best survival-inactive score.
Construction of a Novel Active D2R Model. Our active D2R
model was based on an active model of the D3R, for which an inactive
crystal structure is available (Chien et al., 2010). The active D3Rmodel
was created by applying a set of spatial constraints obtained by
comparing the inactive and active states of the b2-adrenergic receptor.
In brief, the inactive and active structures of the b2-adrenergic receptor
[PDB ID 2RH1 (Cherezov et al., 2007) and PDB ID 3SN6 (Rasmussen
et al., 2011), respectively] were aligned and, by subtracting the
coordinates of the Ca atoms of the inactive from the active form,
a set of delta coordinates were created. These deltas were added to the
coordinates of the aligned D3R structure to generate a set of spatial
constraints. Using these constraints, the inactivemodel of the D3Rwas
transformed into an active form by using a hybridminimization–Monte
Carlo scheme, implemented in the program Prime (version 3.3;
Schrödinger LLC). The active D3R model was then used as a template
in building the D2R homology model using Prime. Docking of
compounds into the active-state model of the D2R was achieved using
the programGlide (version 6.0; Schrödinger LLC), using the SP scoring
function. To determine the binding mode of the congeneric series,
a single reference compound (MLS1547) was first docked in the
orthosteric binding site (OBS) revealed by the bound eticlopride in the
D3R structure, which is formed by residues from transmembranes
(TMs) 3, 5, 6, and 7. We found the pyridine moiety of MLS1547
preferred to point toward TM2. Interestingly, for two well studied
D2R antagonists, spiperone and azaperone, that share a common
4-fluophenyl-4-butanone moiety, as proposed/validated previously
(Boeckler et al., 2005), if we assume that such a moiety is bound in
the OBS, then the pyridine moiety of azaperone points toward TM2,
similar to MLS1547 (data not shown). We also docked MLS1547 in
another D2R model in an active conformation based on a D3R active
model (Newman et al., 2012) and equilibrated using molecular
dynamics simulations. Encouragingly, results from both D2R models
were consistent. All other compounds were then docked using core
constraints on the core substructure shared by all compounds to ensure
the core in the OBS adopted a similar binding mode.
Results and Discussion
In an effort to discover G protein–biased agonists of the D2R,
we screened the ∼380,000-compound small-molecule library in
the Molecular Libraries Probe Production Center Network at
the National Center for Advancing Translational Sciences. The
primary screen used a stably transfected cell line expressing the
human D2R and a chimeric Gqi5 protein enabling robust
calcium mobilization upon activation of the D2R. This screen
identified 2288 compounds with significant D2-Gqi5 agonist
activity, defined as compounds that, when screened at 40 mM,
elicited a response larger than 3-fold over the standard deviation
of mean signal from control wells with no compound. Agonists
were also screened for calcium mobilization in a parental,
nontransfected cell line, and any compound showing activity
was eliminated. The active compounds were then subjected to
verification by generating full concentration-response curves
for each compound. Subsequently, the hit compounds that
exhibited full dose response–activity relationships were evalu-
ated in two orthogonal assays—one was to evaluate their ability
to inhibit cAMP accumulation, a primary G protein signaling
mechanism for the D2R (Bateup et al., 2008), and the other was
to test their ability to recruit b-arrestin, an important signaling
response independent of G protein activation (Beaulieu et al.,
2007a, 2008). As would be expected, our results revealed that
the vast majority of the hit compounds were equally active in
both the G protein– and b-arrestin–mediated signaling assays
(e.g., see Supplemental Fig. 1). However, a small subset of hits
(about two dozen) showed greatly diminished efficacy and/or
potency in the b-arrestin recruitment assay (see Supplemental
Material for screening details). One of these compounds,
MLS000051547 (MLS1547; Fig. 1A), was selected for further
characterization as it appeared to have high efficacy in the
G protein–mediated signaling assays, but no measurable ac-
tivity in the b-arrestin recruitment assay.
Indeed, Fig. 1B shows that MLS1547 behaved as a highly
efficacious agonist in the D2-Gqi5 calciummobilization assay,
with an EC50 value of 0.37mMand anEmax of∼90%. To ensure
that this activity is physiologic, and not restricted to the
chimeric G protein nature of the Gqi5 assay, we examined the
ability of MLS1547 to inhibit forskolin-stimulated cAMP
accumulation in cells stably expressing the D2R. Figure 1C
shows that, similar to dopamine, MLS1547, completely
inhibited the stimulation of cAMP by forskolin, with an
EC50 of 0.26 mM suggestive of it having high efficacy at D2R-
mediated G protein–linked signaling. We further found that
the inhibition of cAMP accumulation by MLS1547 was
completely blocked by cotreatment with the D2R antagonist
sulpiride, as shown in Fig. 1D. The IC50 of 22 nM for sulpiride’s
inhibition of MLS1547’s action is similar to sulpiride’s potency
for blocking dopamine’s response in this cAMP assay (data not
shown). Taken together, these data indicate that MLS1547 is a
highly efficacious agonist at the D2R for stimulating G protein–
mediated signaling.
The ability of MLS1547 to stimulate recruitment of
b-arrestin to the D2R was evaluated using the DiscoveRx
b-arrestin PathHunter assay, which relies on the comple-
mentation and activation of b-galactosidase when b-arrestin-
2 is recruited to the receptor. Notably, b-arrestin-2 is the
b-arrestin protein functionally coupled to the D2R in vivo
(Skinbjerg et al., 2009). Whereas incubation with dopamine
resulted in robust recruitment of b-arrestin-2 in a dose-
dependent manner, MLS1547 failed to exhibit activity in this
assay (Fig. 2A), despite it being a highly efficacious agonist of
G protein–mediated signaling. However, other possible ex-
planations for these discrepant results could include inter-
ference of the compound with the enzyme-linked signaling,
resulting in a suppression of signal. To address these al-
ternative explanations, we used a BRET assay that directly
measures the physical interactions between the b-arrestin-2
protein and the D2R. Furthermore, this also serves as
a control for a different cell background, as these assays were
conducted in human embryonic kidney 293 cells. As seen in
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Fig. 2B, however, MLS1547 failed to stimulate any observable
recruitment of b-arrestin-2 to the D2R in this assay, despite
robust recruitment by dopamine. Taken together, these
findings indicate that, although MLS1547 is a highly ef-
ficacious agonist at G protein–mediated signaling, it is
unable to stimulate measurable b-arrestin recruitment, thus
establishing it as an extremely G protein–biased agonist at
the D2R.
Since MLS1547 activates G protein–linked pathways, yet
does not stimulate b-arrestin recruitment, MLS1547 would be
expected to antagonize the dopamine-induced b-arrestin
response by blocking dopamine binding to the receptor. As
seen in Fig. 2C, MLS1547 fully antagonized dopamine-
mediated b-arrestin recruitment to the D2R in the DiscoveRx
assay, with an IC50 of 9.9 mM. Similar results were obtained
when MLS1547 was examined for antagonist activity in the
D2R b-arrestin BRET assay, demonstrating an IC50 of 3.8 mM
(Fig. 2D). In summary, although MLS1547 is an agonist of
D2R-stimulated G protein–mediated signaling, it acts as an
antagonist of the b-arrestin–mediated signaling pathway.
To determine the affinity of MLS1547 for the D2R, we used
standard radioligand binding competition analyses. MLS1547
was found to completely displace [3H]methylspiperone binding
to the D2R, with a calculated Ki value of 1.2 6 0.2 mM (Fig. 3).
Displacement studies were also conducted on the other
dopamine receptor subtypes (Supplemental Fig. 2), resulting
in mean 6 S.E.M. Ki values of 2.3 6 0.2 mM (D3R) and 0.32 6
0.04 mM (D4R) (n5 3), suggesting a less than 10-fold difference
in affinity between the members of the D2-like family. When
the D1-like receptors were examined by measuring the ability
of MLS1547 to displace [3H]SCH23390 binding to D1 and D5
receptors, the extrapolated Ki values for both receptors were
.50 mM (Supplemental Fig. 2).
A series of MLS1547 analogs were either obtained from
commercial sources or, in a few cases, synthesized to investigate
the structure-activity relationship (SAR) of pathway selectivity
for this set of compounds (for purity and manufacturer, see
Supplemental Table 1). These analogs were assayed in the D2R
cAMP assay as well as in the DiscoveRx b-arrestin recruitment
assay (Tables 1 and 2). Although none of the analogs were more
potent than MLS1547, a subset of the analogs was also
extremely G protein–biased such that they lacked b-arrestin
recruitment activity (Table 1). However, another subset of
compounds exhibited agonist activity in both the cAMP and
b-arrestin assays with variable degrees of G protein signaling
bias (Table 2). These findings were used to formulate a pre-
liminary SAR of G protein bias in this series of compounds.
To do this, a pharmacophore model was constructed to dis-
tinguish between the completely G protein–biased (Table 1)
and less/nonbiased D2R agonists (Table 2). Specifically, we
selected 10 compounds, displaying either the strongest or
weakest G protein bias, and then assigned default pharma-
cophore features [positive (P), acceptor (A), donor, aromatic
(R), and hydrophobic (H)] to these ligands (see Materials and
Methods). We found that a 4-point HRPR hypothesis was best
able to explain the experimental data (Fig. 4, A and B).
Specifically, the alignment of the H feature in these com-
pounds is the key difference between the completely biased
(Table 1) and less/nonbiased (Table 2) agonists of this scaffold.
As shown by two representative biased/nonbiased pairs in
Fig. 1. MLS1547 stimulates D2R G protein–mediated signaling. (A) Structure of MLS000051547 (MLS1547). (B) Human embryonic kidney 293 cells
stably expressing D2R and Gqi5 were assayed for MLS1547 stimulation of calcium accumulation, as described in Materials and Methods. Cells were
stimulated with the indicated concentrations of dopamine (DA) or MLS1547 (1547). EC50 and Emax values were obtained for dopamine (2.56 0.3 nM and
101.7%6 0.1%, respectively) and MLS1547 (0.376 0.2 mM and 89.3%6 4.3%, respectively) (mean6 S.E.M., n = 3). (C) CHO cells stably expressing the
D2R were assayed for MLS1547 inhibition of forskolin-stimulated cAMP, as described in Materials and Methods. Cells were stimulated with the
indicated concentration of dopamine or MLS1547 (1547). EC50 and Emax values were obtained for dopamine (0.06 6 0.02 mM and 100.4% 6 1.6%,
respectively) and MLS1547 (0.266 0.07 mM and 97.1%6 3.7%, respectively) (mean6 S.E.M., n = 5). (D) CHO cells stably expressing D2R were assayed
for sulpiride reversal of MLS1547 inhibition of forskolin-stimulated cAMP accumulation. Cells were stimulated with an EC80 concentration of MLS1547
(1547) in the presence of increasing concentrations of the D2R antagonist sulpiride. The IC50 value obtained for sulpiride was 22.0 6 2.8 nM (mean 6
S.E.M., n = 4). Data are representative of three to five independent experiments run in triplicate and plotted as a percentage of the maximum response
observed with dopamine (B and C), or as a percentage of the response seen with an EC80 concentration of MLS1547 (D), as indicated.
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Fig. 4, the completely biased compounds align optimally to the
H feature, whereas the less/nonbiased compounds do not (Fig.
4, A and B).
In parallel, we docked these compounds into a novel active-
state model of the D2R using MLS1547 as a reference com-
pound. For theMLS1547 compound, we observed two plausible
orientations with the pyridine moiety pointing toward either
TM5 in the OBS or toward TMs 2 and 7, away from the OBS
(data not shown). Based on the SAR derived from Table 1, it
appears that the N in the pyridine ring likely makes an H bond
with a receptor residue, as there is a ∼10-fold increase in the
potency of MLS1547 compared with that of NCGC319125.
When the pyridine points toward TM5, however, a correspond-
ing H-bond donor cannot be identified in the OBS. Thus, it is
more likely that MLS1547 adopts the alternate orientation
with the pyridine pointing toward TMs 2 and 7, in which the N
on the pyridine ring may interact with Thr369 in TM7 to form
anHbond. These docking results were confirmed using amodel
with the D2R in an active conformation based on another D3R
active model (Newman et al., 2012) and equilibrated using
molecular dynamics simulations (data not shown). Encourag-
ingly, results from both models were similar.
Using the MLS1547 pose with the pyridine pointing toward
TMs 2 and 7, we used a core-restrained protocol to dock the
other compounds into the active D2R model to compare the
binding modes of the fully G protein–biased versus less/
nonbiased agonists. The resulting poses show that the com-
pletely biased compounds from Table 1 have a significantly
higher tendency to interact with the extracellular portion of
TM5. Specifically, the chloro (2Cl) group of MLS1547 interacts
Fig. 2. MLS1547 acts as an antagonist for dopamine (DA)-stimulated b-arrestin recruitment to the D2R. (A) DiscoveRx PathHunter cells were assayed
for agonist-induced recruitment of b-arrestin-2 to the D2R as described in Materials and Methods. Cells were stimulated with the indicated
concentrations of dopamine or MLS1547 (1547), and EC50 and Emax values were obtained for dopamine (0.096 0.03 mM and 99.0%6 0.6%, respectively;
mean6 S.E.M., n = 3). MLS1547 failed to stimulatemeasurable b-arrestin-2 recruitment. (B) Human embryonic kidney 293 cells were stably transfected
with Rluc-8–fused D2R and mVenus-fused b-arrestin-2, stimulated with various concentrations of dopamine or MLS1547 (1547) as indicated, and
examined for BRET as described in Materials and Methods. EC50 and Emax values obtained for dopamine were 0.05 6 0.01 mM and 99.8% 6 1.9%,
respectively (mean6 S.E.M., n = 3). MLS1547 failed to stimulate anymeasurable D2R–b-arrestin-2 interactions. Data are representative of three to five
independent experiments run in triplicate and plotted as a percentage of maximum response observed with dopamine as indicated. (C) DiscoveRx
PathHunter cells were stimulated with an EC80 concentration of dopamine (1 mM), then assayed for the ability of MLS1547 to antagonize this response.
Data are expressed as the percentage of the maximum response observed with 1 mM dopamine and represent the mean 6 S.E.M. values of three
individual experiments performed in triplicate. The IC50 value for MLS1547 was calculated to be 9.9 6 0.9 mM. (D) The same cells described for the
BRET assay in B were stimulated with an EC80 of dopamine (1 mM) and assayed for the ability of MLS1547 to antagonize this response. Data are
expressed as mean values of six independent experiments run in quadruplicate. The IC50 value for MLS1547 was 3.8 6 1.8 mM (mean 6 S.E.M., n = 6).
Fig. 3. Radioligand binding competition assay using MLS1547 and the
D2R. Membranes from human embryonic kidney 293 cells stably trans-
fected with the human D2R were harvested for radioligand competition
binding assays as described in Materials and Methods. Membranes were
incubated with the indicated concentrations of MLS1547 and 0.5 nM
[3H]methylspiperone. The data are representative of four independent
experiments and expressed as a percentage of the binding seen in the
absence of any competing ligand. The Ki for MLS1547 was calculated to be
1.2 6 0.2 mM (mean 6 S.E.M., n = 4).
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with a hydrophobic pocket formed by Ile184EL2, Phe1895.38,
and Val1905.41 (Fig. 4) (PDB ID D2, MLS1547; Supplemental
Data). Interestingly, this is consistent with our finding from
the pharmacophore modeling that the fully G protein–biased,
but not the less/nonbiased compounds, can be well aligned to
the H feature of the aforementioned HRPR pharmacophore
(PDB ID NCGC9141, NCGC5872, NCGC5873; Supplemental
Data). Although recent publications suggest a possible role
for aromatic 2Cl groups in an H-bond formation, it is not
atypical to consider 2Cl as a hydrophobic group as well.
Indeed, there are multiple examples in the literature where
a methyl/2Cl swap resulted in roughly the same potency,
and was better tolerated than the unsubstituted hydrogen
(Baum et al., 2009).
Thus, it is tempting to speculate that the structural basis
for the different efficacies of these two groups of agonists
critically depends on whether a compound can interact with
the hydrophobic pocket near the extracellular portion of TM5
mentioned earlier. Interestingly, interactions with the extra-
cellular portion of TM5 have previously been proposed as the
structural basis for the b-arrestin signaling bias of the
serotonergic agonist ergotamine at the 5-hydroxytryptamine
(5HT)2B receptor, whereas ergotamine is notably nonbiased
at the related 5HT1B receptor (Wacker et al., 2013). Thus,
TABLE 1
Analogs of MLS1547 active in cAMP assays yet lacking b-arrestin recruitment activity
The compounds were assayed in agonist mode using the DiscoveRx cAMP and b-arrestin assays as described in Materials and Methods.
Structure Compound ID









MLS000051547 97.1 6 3.7 0.26 6 0.07 2.57 Inactive NA
NCGC00319124 87.3 6 14.7 5.5 6 0.9 1.20 Inactive NA
NCGC00319127 93.9 6 4.6 4.7 6 1.7 1.30 Inactive NA
NCGC00319125 66.8 6 3.9 2.8 6 1.2 1.38 Inactive NA
NCGC00346387 94.8 6 2.1 1.4 6 0.8 1.83 Inactive NA
NCGC00319141 89.5 6 5.2 0.7 6 0.7 2.11 Inactive NA
MLS000860449 84.9 6 2.7 4.5 6 3.0 1.28 Inactive NA
NCGC0319129 74.8 6 23.8 9.5 6 5.6 0.90 Inactive NA
NCGC00319126 62.8 6 7.7 1.1 6 0.6 1.76 Inactive NA
Dopamine 100 0.06 6 0.02 3.22 100 0.09 6 0.03
NA, not applicable.
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TABLE 2
Analogs of MLS1547 active in both cAMP and b-arrestin assays
The compounds were assayed in agonist mode using the DiscoveRx cAMP and b-arrestin assays as described in Materials and Methods.
Structure Compound ID














NCGC00319139 95.5 6 2.0 0.03 6 0.01 3.50 89.3 6 9.4 2.0 6 0.5 1.65 1.85
NCGC00319137 84.1 6 4.5 0.02 6 0.001 3.62 84.7 6 2.5 1.6 6 0.3 1.72 1.90
NCGC00319136 93.8 6 1.4 0.1 6 0.04 2.97 76.4 6 2.9 0.7 6 0.07 2.04 0.93
NCGC00092785 77.0 6 10.9 0.04 6 0.01 3.28 73.8 6 1.2 0.4 6 0.02 2.27 1.02
NCGC00319134 86.1 6 14.4 0.1 6 0.04 2.94 74.7 6 1.8 0.3 6 0.03 2.40 0.54
NCGC00319131 89.6 6 0.5 0.2 6 0.1 2.65 66.0 6 0.2 0.8 6 0.01 1.92 0.73
NCGC00319132 78.9 6 10 0.1 6 0.01 2.90 59.2 6 4.2 0.3 6 0.04 2.30 0.60
NCGC00319133 86.5 6 14.7 0.01 6 0.001 3.94 87.6 6 2.0 0.2 6 0.03 2.64 1.30
NCGC00319130 71.0 6 17.1 0.1 6 0.02 2.85 66.0 6 0.2 2.1 6 0.4 1.50 1.35
NCGC00319135 83.3 6 14.4 1.4 6 0.1 1.77 68.9 6 4.9 13.2 6 6.6 0.72 1.06
NCGC00319140 92.5 6 5.5 2.0 6 0.2 1.67 66.2 6 18.6 20.5 6 9.6 0.51 1.16
NCGC00319128 97.2 6 0.7 0.4 6 0.1 2.39 70.0 6 5.9 3.4 6 0.5 1.31 1.07
NCGC00346388 90.9 6 1.9 0.2 6 0.1 2.66 56.8 6 7.1 1.0 6 0.6 1.75 0.90
NCGC00345872 97.1 6 0.9 0.3 6 0.1 2.51 58.0 6 8.4 0.9 6 0.3 1.81 0.70
(continued )
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comparing crystal structures of ergotamine bound to both
receptors, it was found that the extracellular portion of TM5 is
tilted significantly more toward the OBS in the 5HT2B
receptor, compared with the 5HT1B receptor (Wacker et al.,
2013). This suggests a mechanism whereby agonists that
prevent such a tilting would bias toward G protein activation,
compared with the b-arrestin pathway. Future experiments
to test this SAR prediction for the D2R and other GPCRs will
be required. It is interesting to note, however, that in the D2R,
mutations of four residues at the cytoplasmic end of TM5
disrupt b-arrestin recruitment much more than they impact
cAMP signaling (Lan et al., 2009), suggesting that differential
propagation of signals through TM5 may play an important
role in determining signaling bias.
In summary, MLS1547 is the first example of a G protein–
biased agonist of the D2R. Although it robustly activates
G protein–mediated signaling, the compound does not pro-
mote b-arrestin recruitment to the receptor. Rather, through
occupancy of the receptor, MLS1547 functions as an antag-
onist of dopamine-induced b-arrestin recruitment to the D2R.
Administration of compounds with this pharmacological
profile to animals would be expected to stimulate G protein–
based signaling of the D2R while simultaneously inhibiting
signaling through the b-arrestin/Akt/GSK3b pathway. Such
compounds may also engender less b-arrestin–mediated re-
ceptor desensitization or internalization, thereby further am-
plifying the G protein signaling arm. Importantly, MLS1547,
despite displaying no measurable b-arrestin recruitment
in our assays, appears to be a highly efficacious agonist
at G protein–mediated signaling for the D2R. Recently,
b-arrestin–biased agonists have been developed for the D2R
that exhibit varying degrees of agonist efficacy (Allen et al.,
TABLE 2—Continued
Structure Compound ID














NCGC00345873 93.1 6 1.6 0.1 6 0.07 2.97 63.3 6 8.9 0.9 6 0.6 1.85 1.12
Dopamine 100 0.06 6 0.02 3.22 100 0.09 6 0.03 3.05 0.18
Fig. 4. Pharmacophore model for G protein–
biased and nonbiased agonist interactions with
the D2R. (A and B) HRPR pharmacophore with
aligned biased compounds MLS1547 and
NCGC9141. Biased compounds align well to all
four features: two aromatic (beige), one hydro-
phobic (green), and a positive (blue) feature.
(Middle) Compared with the biased compound
MLS1547, the nonbiased compound NCGC5872
(left) lacks the 2Cl group and cannot align both
the hydrophobic and aromatic features, whereas
the different attachment points of the naphtha-
lene ring in compounds NCGC9141 and
NCGC5873 cause the former, but not the latter,
to align well to the 4-point pharmacophore. In
this case, one of the aromatic rings in NCGC9141
aligns the hydrophobic feature. (C and D) Docked
poses of biased (cyan) and unbiased (gray)
compounds in an active model of the D2R. Note
the more extensive interaction of nonpolar
features in the biased compounds with a hydro-
phobic pocket formed by residues in EL2 and
TM5.
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2011; Chen et al., 2012). Functionally selective probes for both
of the major signaling arms of the D2R should now help to
dissect their roles in normal physiology and behavior as well
as elucidate their involvement in the therapeutic effects of
various pharmaceutical agents.
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